Question 1

What is larazotide medication used for?

Accepted Answer

Larazotide was developed for one purpose: helping people with coeliac disease whose gut still reacts to gluten. Coeliac disease is an immune reaction to gluten that damages the lining of the small intestine. A 2019 review notes that it is managed using a strict and lifelong gluten-free diet, the only effective treatment available. Larazotide was meant to sit alongside that diet rather than replace it. A 2021 review describes larazotide acetate as a single-chain peptide of eight amino acids that acts as a tight junction regulator to restore intestinal barrier function. Tight junctions are the seals between the cells that line the gut. The same review says it is given by mouth to adults with coeliac disease as an adjunct, which means an add-on to existing care. A 2016 review is plainer still, calling it a synthetic peptide developed as a permeability regulator primarily targeting coeliac disease. Everything else it has been tried for, from arthritis in mice to children made ill after COVID-19, came later and grew out of that single gut idea.

Question 2

Has larazotide been tested in people?

Accepted Answer

Yes, and more thoroughly than most research compounds, though in a narrow group of patients. A 2022 meta-analysis, a study that pools the results of earlier trials, found four randomised controlled trials comprising 626 patients, with 465 given larazotide and 161 given placebo. All of them had coeliac disease. The earliest trial behind this page was a 2007 in-patient, double-blind study in people with coeliac disease who were then challenged with gluten on purpose. The largest enrolled 342 adults who had been on a gluten-free diet for at least a year and were still having symptoms. Outside coeliac disease, a 2025 phase 2a trial tested larazotide against placebo in 12 children with multisystem inflammatory syndrome, a severe illness that follows COVID-19 in some children. So the human record is real, and most of it is placebo-controlled. It is also short, mostly adult and almost entirely about one disease, which limits what it can say about anyone outside those groups.

Question 3

Does larazotide actually work?

Accepted Answer

Partly, and the pattern of where it worked is the most informative detail available. In the 342-adult trial, the primary end point was met with the 0.5-mg dose, with fewer symptoms than placebo. The 1 mg and 2 mg doses, however, were no different from placebo on any end point. A larger amount accomplishing nothing while a smaller one helps is not the pattern a straightforward biological effect usually produces, and it is the first thing a careful reader should notice. The pooled 2022 analysis then split the results by gluten. Larazotide beat placebo on symptom scores in patients deliberately given gluten, but showed no significant difference in patients simply staying on their gluten-free diet. A 2025 review of new paediatric gut treatments put the overall position in four words: clinical outcomes are inconsistent. That is not a verdict that it fails, and it is not evidence that it works either. Each outcome, including what happened to the permeability test, is taken apart on the Larazotide benefits page.

Question 4

Why was larazotide discontinued?

Accepted Answer

The Phase 3 trial ended early, and its registry record says who stopped it but not why. Its entry on ClinicalTrials.gov, a randomised, double-blind, placebo-controlled study in adults with coeliac disease on a gluten-free diet, lists the trial as terminated, with the reason given in four words: trial terminated by Sponsor. The record shows the study started on 29 May 2019 and ended on 21 July 2022 with 307 people enrolled, under the lead sponsor 9 Meters Biopharma. Until then the literature described the programme in the present tense. A 2021 review states that larazotide was then being studied in phase III clinical trials, the large confirmatory stage that precedes an application for regulatory approval. A 2021 pig study similarly describes it as a small peptide studied in Phase III clinical trials for coeliac disease. A 2020 paper on COVID-19 went further, saying it was in phase 3 trials with strong safety and efficacy profiles. That last characterisation came from authors proposing larazotide for another use, not from a published trial result. What the record does not give is a result, or any reason beyond the sponsor's decision, and none of the research behind this page reports one. A trial that missed its primary goal and a commercial decision would say very different things about the compound, so we do not choose between them. A 2024 review of coeliac treatments sums up where the field stands: despite significant efforts, no treatment has yet completed a phase III clinical trial.

Question 5

Where does larazotide sit among the coeliac treatments in development?

Accepted Answer

In one of five broad lines of attack, and the reviews do not name a winner among them. A 2019 paediatric review sorts the field into five broad approaches by target. They are making gluten less harmful, binding it inside the gut, stopping it slipping between gut cells, blocking an enzyme that sharpens the immune response, and calming that immune response afterwards. Larazotide belongs to the third group, which the same review describes as stopping digested gluten from passing through the tight junctions, using a zonulin antagonist. A 2021 review names larazotide and latiglutenase, a gluten-digesting enzyme, as two of the further advanced clinical programmes. A 2025 review, covering enzymes, gluten binders, permeability modulators, immune drugs and tolerance vaccines, concludes that none has yet been conclusively shown to replace the diet. So the honest answer to which one leads is that none has displaced the gluten-free diet. Larazotide's own trials point toward an add-on role, rather than a way back to eating gluten.

Question 6

Is coeliac disease something you are born with, or does it develop later?

Accepted Answer

Both, in a sense: the susceptibility is inherited, but the disease itself can be activated at almost any stage of life. A 2008 review describes coeliac disease as a genetic condition that is triggered, or becomes active for the first time, after surgery, pregnancy, childbirth, viral infection, or severe emotional stress. A 2009 review adds that the disease can occur at any age, with the greatest occurrence in early adulthood. The same 2008 review estimated that about 1 in 133 people in the United States have it. For larazotide this matters in one specific way. Its entire rationale is that gluten fragments penetrate an intestinal lining that has become abnormally permeable. A disease that can be activated later in life, by an infection or a pregnancy, is consistent with the idea of a barrier that changes over time. Consistency is not the same as proof, though, and whether a leaky barrier causes coeliac disease or follows from it remains disputed in the reviews. That debate is set out on the Larazotide benefits page.

Question 7

How is larazotide taken in studies?

Accepted Answer

By mouth, several times daily, with later formulation work aimed at releasing it where coeliac disease inflicts its damage. A 2013 trial report calls it a first-in-class oral peptide that prevents tight junction opening. A 2021 pig study tested a delayed-release version that was predicted to release in the mid duodenum and jejunum, the first stretches of small intestine after the stomach, which is where coeliac damage sits. That design choice is a reminder of how larazotide was intended to work. It was engineered to act on the intestinal lining from the inside, rather than to circulate throughout the body in the bloodstream. Outside coeliac disease the schedule changed: children in the inflammatory syndrome trial were treated four times daily for three weeks, on top of their hospital care. The specific amounts, how often they were given and what happened when the amount went up are reported as trial parameters on the Larazotide dosage page, together with the reasons none of them amounts to a protocol for anyone else.

Question 8

What side effects are documented for larazotide?

Accepted Answer

Few, and none that clearly separated larazotide from placebo in the controlled trials. In the 342-adult trial, the report states simply that safety was comparable with placebo. In a 2012 dose-ranging trial of 86 adults, no serious adverse events were observed. Those two statements are the headline, and both come from randomised trials in which a placebo group was monitored identically. None of that amounts to a demonstration that larazotide is harmless. The trials were brief, modest in size by the standards of medicine development, and confined mostly to adults with a single disease who were already following a strict diet. Rare harms, harms that accumulate over months, and harms in populations the trials excluded cannot surface in a record of that kind. The specific adverse events recorded, the exclusions, the length of observation and the experience in children are examined individually on the Larazotide safety page.

Question 9

Is larazotide approved, and how much does it cost?

Accepted Answer

It is not approved by the FDA for any use, and no price for it appears among the sources behind this page. A 2021 review states that no FDA-approved medication exists for coeliac disease, and the same review lists larazotide among the programmes still in clinical trials. A 2014 review made the same point in different words: there were no licensed therapeutic options for coeliac disease outside a gluten-free diet. Without an approval there is no pharmacy listing, no insurance price and no official label, which is why searches for its cost turn up nothing authoritative. The trial results belong to the material those trials actually used, made for that purpose and given under supervision. Material offered under the name outside a trial comes with no approved specification behind it, so the trial findings cannot simply be carried over to it.

Question 10

What else has larazotide been tested for?

Accepted Answer

A widening list, most of it in animals and cells. A 2021 review that screened 209 publications grouped the work by disease: coeliac disease, type 1 diabetes, other autoimmune diseases, inflammatory bowel disease, Kawasaki disease, and respiratory disease. The review's own conclusion rests on work done in vivo and in vitro, meaning in living animals and in laboratory dishes. One example shows the style of the animal work. In mice heading toward arthritis, larazotide effectively reduced arthritis onset, in a 2020 study arguing that a leaky gut helps turn silent autoimmunity into joint inflammation. The only human use outside coeliac disease is the post-COVID inflammatory syndrome in children, where a small trial and a handful of individual cases gave it alongside standard hospital care. A long list of animal models is not the same thing as a long list of human results, and it is worth keeping the two apart. What each of these experiments measured is laid out on the Larazotide benefits page.

Question 11

Is AT-1001 always larazotide?

Accepted Answer

No, and anyone searching the literature by code needs to know it. AT-1001 is larazotide's development code, but the same label has been attached to two unrelated molecules. A 2015 paper on Fabry disease, an inherited enzyme disorder, uses AT1001 as the code for migalastat, a chaperone that props up a faulty enzyme. A 2013 study under that same code gave single oral doses of migalastat to 14 healthy male volunteers, which a search for AT-1001 safety data will happily return. The second namesake comes from addiction research. A 2015 rat study describes an AT-1001 that blocks nicotine self-administration in rats by acting on a nicotine receptor in the brain. A companion paper gives its chemical structure, a small ring compound that is not a peptide at all. Neither molecule has anything to do with the gut lining. Larazotide acetate is the name to search, and every result on this page uses it or comes from the coeliac and inflammation work.

Question 12

How is larazotide thought to work?

Accepted Answer

By keeping the seals between gut cells closed, although exactly which switch it flips is less settled than short descriptions suggest. The original idea centres on zonulin, a protein the body makes that loosens those seals. The 2021 mechanism review says larazotide is thought to act as a zonulin antagonist, damping zonulin-driven increases in permeability. The same review adds a second route, saying it has more recently been linked to blocking myosin light chain kinase, an enzyme that pulls on the cell's internal scaffolding. A 2025 mouse study calls a receptor named PAR2 the primary receptor for zonulin, and later papers describe larazotide itself as a PAR2 antagonist. Yet a 2021 paper is titled 'Lack of relationship of AT1001 to zonulin and prehaptoglobin-2: clinical implications', which signals real disagreement about the zonulin story itself. Its origin is unexpected too: its structure is derived from a protein secreted by Vibrio cholerae, the organism that causes cholera. A contested mechanism does not cancel the trial results, but it does mean the leaky-gut explanation is a theory rather than a measured fact.

Question 13

How does larazotide relate to other gut research compounds?

Accepted Answer

It shares a target with several of them, but very little evidence, so they are best read separately. KPV, a three-amino-acid fragment of a skin-darkening hormone, has been studied for gut inflammation in animal and cell models, and its record is set out at the KPV overview. BPC-157, a peptide first found in gastric juice, has been studied for gut and tendon repair in animal models, and that record lives at the BPC-157 overview. VIP, vasoactive intestinal peptide, is a hormone the body makes in its own nerves, including those of the gut, and the VIP overview covers what has been measured for it. Within coeliac research larazotide is not alone either. A 2026 review in Gut groups it with IMU-856 among the experimental medicines aimed at restoring the gut barrier. Among the studies behind this page, combinations appear only in animal work, such as a 2025 mouse study that loaded larazotide into an antibacterial gel for colitis. None of these pairings has been given to a person among the studies behind this page, and separate evidence bases cannot be added together into a result for a mixture.

Larazotide